Genuine Biotech Seeks IPO Booster from New Oral Covid Drug
Company hopes China’s approval of its small molecule oral Covid-19 drug will draw investors to its newly filed listing plan Key Takeaways: Genuine Biotech has filed to list in Hong…
Recent Articles
RELATED ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
